{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-027180","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.837687+00:00","generated_at":"2026-06-10T06:50:51.374994+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vistagen stockholders re-elect directors, approve equity plan increase to 1M shares","bullets":["Seven director nominees re-elected; votes for ranged from 1.44M to 1.67M, withholds 416k to 642k.","Advisory say-on-pay approved with 1.38M for, 607k against, 96k abstain.","Amendment to 2019 Omnibus Equity Incentive Plan approved: authorized shares increased from 600k to 1M.","Ratification of WithumSmith+Brown as auditors for FY ending March 31, 2024 approved (3.93M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-027180","json":"https://secwatch.observer/filing/0001437749-23-027180.json","markdown":"https://secwatch.observer/filing/0001437749-23-027180.md","text":"https://secwatch.observer/filing/0001437749-23-027180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/vtgn20230921_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:50:51.374994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2883192a01bbc143ba5c3d436f7214237327994f","claim":"Vistagen Therapeutics, Inc. shareholders approved Election of Directors at the 2023-09-25 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Directors For Withheld Ann M. Cunningham, MBA 1,443,789 641,810","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-25"}],"fact_type":"shareholder_vote"},{"claim_id":"9c4d3fa7747728d90f8c4234ac11fc3ae91d0cfb","claim":"Vistagen Therapeutics, Inc. shareholders approved Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) at the 2023-09-25 meeting.","evidence_excerpt":"Proposal No. 2 – Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) For Against Abstain Votes 1,382,535 607,263 95,801","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-25"}],"fact_type":"shareholder_vote"},{"claim_id":"cf26c88771692681d08d1266ef104f90831d0894","claim":"Vistagen Therapeutics, Inc. shareholders approved Ratification of Appointment of Auditors at the 2023-09-25 meeting.","evidence_excerpt":"Proposal No. 4 – Ratification of Appointment of Auditors For Against Abstain Votes 3,933,402 334,951 42,733","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-25"}],"fact_type":"shareholder_vote"},{"claim_id":"f26b5a84ffd946731588f0c98cefe433aed3fa8e","claim":"Vistagen Therapeutics, Inc. shareholders approved Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan at the 2023-09-25 meeting.","evidence_excerpt":"Proposal No. 3 – Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan For Against Abstain Votes 1,389,517 667,326 28,756","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}